Century Therapeutics (IPSC) Operating Margin (2022 - 2025)
Century Therapeutics (IPSC) posted quarterly Operating Margin of 67.95% for Q1 2025, up 372982.0% year-over-year from N/an in Q1 2024, and up 107.61% quarter-over-quarter from 893.46% in Q4 2024.
Century Therapeutics (IPSC) Operating Margin (2022 - 2025) Analysis & Trends
Century Therapeutics (IPSC) has reported Operating Margin for 4 consecutive years, with 67.95% the latest figure, recorded in Q1 2025.
- In Q1 2025, Operating Margin rose 372982.0% year-over-year to 67.95%; the TTM figure through Dec 2025 stood at 15.81% (up 208035.0% YoY), while the FY2025 annual figure was 15.82%, up 208066.0% from the prior year.
- Operating Margin climbed to 67.95% in Q1 2025 per IPSC's latest filing, from 893.46% in the prior quarter.
- Across five years, Operating Margin topped out at 67.95% in Q1 2025 and bottomed at 35431.31% in Q2 2023.
- Historically, Operating Margin has averaged 8053.42% across 4 years, with a median of 3661.87% in 2024.
- Annual changes were most pronounced in 2023 — Operating Margin sank 3318554 bps — and 2024, when it soared 3092353 bps.
- Century Therapeutics' Operating Margin stood at 6392.71% in 2022, then slumped by 155 bps to 16329.1% in 2023, then jumped by 95 bps to 893.46% in 2024, then soared by 108 bps to 67.95% in 2025.
- Business Quant data shows IPSC's Operating Margin at 67.95% in Q1 2025, 893.46% in Q4 2024, and 4398.1% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 67.95% |
| Dec 31, 2024 | -893.46% |
| Sep 30, 2024 | -4,398.10% |
| Jun 30, 2024 | -4,507.78% |
| Mar 31, 2024 | -3,661.87% |
| Dec 31, 2023 | -16,329.10% |
| Sep 30, 2023 | -24,071.62% |
| Jun 30, 2023 | -35,431.31% |
| Mar 31, 2023 | -1,865.17% |
| Dec 31, 2022 | -6,392.71% |
| Sep 30, 2022 | -1,427.07% |
| Jun 30, 2022 | -2,245.77% |
| Mar 31, 2022 | -3,538.37% |